CANNAINVESTOR Magazine U.S. Publicly Traded October 2019 | Page 44

46

42

A

GLFI: One of the extremely attractive opportunities available to us is our ability to deliver commodity quantities of high margin, rare cannabinoids. As more and more medical and health products are being developed, many are increasingly requiring the more rare cannabinoids. Because of the potentially large scale of our cultivation operation we will be uniquely positioned to work hand-in-hand with these product developers to produce large quantities of specific, rare compounds on an upfront, contract basis.

CIM: What are the risks associated with your business? How are you impacted by United States legislation, considering the fact it is still federally illegal?

Q

GLFI: By operating in Argentina under a joint venture with an Argentine government entity we have greatly reduced our risks in that country. As a matter of fact, part of our agreement there is to supply product for clinical trials and eventual legalization. There is no shortage of demand for products in those locations were medical marijuana is currently legal and it is our intention to initially focus selling to producers in those territories. As additional legal markets for both medical and recreational marijuana open, we will be prepared to serve them.

CIM: Who are your major Competitors? What separates you from your competitors? What are your strategic differentiators and competitive advantages?

Website: https://glfi.co/

Q

44